Werewolf Therapeutics Merges with Ambros Therapeutics, Secures $150M Funding

Werewolf Therapeutics (HOWL) has announced a merger agreement with Ambros Therapeutics, with the combined entity expected to trade on Nasdaq under the ticker 'AMBX'.

The merged company will have an implied valuation of $500 million, while Werewolf's pre-financing valuation stands at $47.5 million.

As part of the deal, Ambros Therapeutics secured $150 million through a private placement led by RA Capital Management and Janus Henderson Investors.

The capital infusion is expected to sustain operations until topline data emerges from the pivotal CRPS-RISE Phase 3 study in 2028.

Neridronate, an investigational therapy under assessment for warm CRPS-1 patients, will be the primary focus of the merged entity.